p53 Immunoreactivity in biopsy specimens of T1G3 transitional cell carcinoma of the bladder - A helpful parameter in guiding the decision for or against cystectomy?

European Journal of Cancer

Volumn 36, Issue 5, 2000, Pages 610-614

  Steiner, G ^a   Bierhoff, E ^a   Schmidt, D ^a   Leissner, J ^b   Wolf, H K ^b   Albers, P ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Bladder cancer; p53; Staging; T1G3 transitional cell carcinoma

Indexed keywords

BIOCHEMICAL MARKER; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTECTOMY; DECISION MAKING; HISTOLOGY; HUMAN; HUMAN TISSUE; MULTICENTER STUDY; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TUMOR BIOPSY;

ADULT; AGED; BIOPSY; CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 0034101302     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00325-1     Document Type: Article

References (14)

1. Pham H.T., Soloway M.S. High-risk superficial bladder cancer: intravesical therapy for T1G3 transitional cell carcinoma of the urinary bladder. Semin. Urol. Oncol. 15:1997;147-153.
2. Hermann G.G., Horn T., Steven K. The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer. J. Urol. 159:1998;91-94.
3. Glick S.H., Howell L.P., Devere White R.W. Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder. J. Urol. 155:1996;1754-1757.
4. Schmitz-Dräger B., Kushima M., Goebell P.et al. p53 and MDM2 in the development and progression of bladder cancer. Eur. Urol. 32:1997;487-493.
5. Hupp T.R., Meek D.W., Midgeley C.A., Lane D.P. Regulation of the specific DNA binding function of p53. Cell. 71:1992;875-879.
6. Finlay C.A., Hinds P.W., Tan T., Eliyahu D., Onren M., Levine A.J. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol. Cell. Biol. 8:1988;531-536.
7. Esrig D., Spruck C.H., Nichols P.W.et al. p53 nuclear protein accumulation correlates with mutation in the p53 gene, tumor grade and stage in bladder cancer. Am. J. Pathol. 143:1993;1389-1396.
8. Sarkis A.S., Dalbagni G., Cordon-Cardo C.et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma. a marker for disease progression J. Natl. Cancer Inst. 85:1993;53-60.
9. Esrig D., Elmajian D., Groshen S.et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med. 331:1994;1259-1264.
10. Hautmann R.E. Complications and results after cystectomy in male and female patients with locally invasive bladder cancer. Eur. Urol. 33(Suppl. 4):1998;23-24.
11. El-Deiry W.S., Tokino T., Velculescu V.E.et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
12. Yew R.P., Berk A.J. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature. 367:1992;82-85.
13. Grimm M.O., Jürgens B., Schulz W.A., Decken K., Makri D., Schmitz-Dräger D.J. Inactivation of tumor suppressor genes and deregulation of the c-myc gene in urothelial cancer cell lines. Urol. Res. 23:1995;293-300.
14. Serth J., Kuczyk M.A., Bokemeyer C.et al. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br. J. Cancer. 71:1995;201-205.